The Short-term Effect of Intravitreal Ranibizumab for Treatment of
Central Serous Chorioretinopathy

Seung Joon Lee

Purpose: To evaluate effectiveness of intravitreal bevacizumab for idiopathic persistent central serous chorioretinopathy(CSC).

Methods: 40 eyes with CSC divided two group. One group(20 eyes) have persistent sensory retinal detachment at least 3 months received intravitreal ranibizumab (IVR) (0.05 mg/0.1 cc) and the other group(20 eyes) didn`t receive intravitreal ranibizumab, and underwent best corrected visual acuity(BCVA), fluorescein angiography(FAG) and optical coherent tomography(OCT) before, 1wk, 1 and 3 months after treatment in both group.

Results: 18 patients among 20 patients received intravitreal ranibizumab showed improvement in BCVA, FAG leakage, and reduced or resolved neurosensory detachment. The best corrected visual acuity of IVR group improved from 0.47±0.39 to 0.86± 0.23 at 1month and is statistical significance compare to control group.

The complete neurosensory retinal detachement was resoved in 18 patients (90%) at 1month and the decrease of foveal thickness from 416μm to 224μm at 1 month was statistical significance in patients received IVR. Three patients who did not show improvement of neurosensory retinal detachment underwent reinjection of ranibizumab, and two of those reinjected showed the resolution of neurosensory retinal detachment at another 1 month. No complication associated with intravitreal ranibizumab injection was seen.

Conclusion: Intravitreal ranibizumab injection is considered have a short-term benefit and might be a fast, effective and safe treatment option for selected patients with idiopathic persistent CSC.